Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Transkaryotic(tktx) -- Ignore unavailable to you. Want to Upgrade?

To: tsq who wrote (111)	1/6/2003 12:04:23 PM
From: tuck	Read Replies (1) \| Respond to of 122

I don't follow this one, so I am not able to even offer an inexpert opinion. The postponed committee meeting is coming up soon: >>ENDOCRINOLOGIC AND METABOLIC DRUGS ADVISORY COMMITTEE DATE AND TIME: January 13, 14, and 15, 8:00 a.m. LOCATION: Holiday Inn, Versailles Ballrooms, 8120 Wisconsin Ave., Bethesda, MD. CONTACT: Karen M. Templeton-Somers, Center for Drug Evaluation and Research, 301-827-7001. On January 13, the committee will discuss the safety and efficacy of biologic licensing application BL 103979, FABRAZYME (agalsidase beta, Genzyme Corp.) for treatment of Fabry’s disease. On January 14, the committee will discuss the safety and efficacy of biologic licensing application BL 103977, REPLAGAL (agalsidase alfa, Transkaryotic Therapies, Inc.) for the treatment of Fabry’s disease. On January 15, the committee will discuss the safety and efficacy of biologic licensing application BL 125058, ALDURAZYME (laronidase, BioMarin Pharmaceutical, Inc.) for the treatment of mucopolysaccharidosis.<< Is there any difference between alfa and beta? One cheaper to manufacture or otherwise less costly than the other? Reasonable questions to ask. Know nothing about the rest of their products and pipeline. Cheers, Tuck